Scientists believe they have discovered a new clue about cell growth which could lead to new drugs to tackle the most deadly form of skin cancer.

Cancer Research UK scientists at the University of Manchester found that some melanoma cells are particularly fast-growing, but not very good at invading the surrounding tissue. In contrast, some melanoma cells are highly invasive but slow-growing, according to the study published in Cell Reports.

In a tumour, the faster growing cells piggy-back along with the more invasive cells and can be more effective in creating a new tumour once they have reached different parts of the body.

See-through zebra fish were used by the researchers to see how the cancer cells moved and grew from the original tumour.

Study author Claudia Wellbrock said: “We used to think that cancer cells spread by first specialising in invading other parts of the body and then change in order to grow rapidly. But this research shows that melanoma can spread by ‘co-operative invasion’.

“Different types of cancer cells with different strengths and weaknesses are both present in the tumour at the same time and can work together to spread faster and more efficiently. This has profound implications for how we find cures for this terrible disease.”

Richard Marais, director of the Cancer Research UK Manchester Institute, pointed out that malignant melanoma is the most deadly form of skin cancer “precisely because it spreads quickly and aggressively”.

Early diagnosis and detecting tumours before they have a chance to spread are valuable tools in tackling the illness along with trying to find ways to treat advanced melanoma, he said.

He said: “This kind of research is vital for establishing how this horrible disease spreads around the body and how we might be able to stop it.”

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.